Theravance Biopharma, Inc. financial data

Symbol
TBPH on Nasdaq
Industry
Pharmaceutical Preparations
Location
Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands
State of incorporation
Cayman Islands
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 520 % -29.9%
Return On Equity -29.7 % -49.3%
Return On Assets -15.6 % -26.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.5M shares +1.72%
Common Stock, Shares, Outstanding 49.5M shares +2.87%
Entity Public Float 335M USD -27%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 48.8M shares -11.7%
Weighted Average Number of Shares Outstanding, Diluted 48.8M shares -11.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 64.4M USD +12.1%
Research and Development Expense 37.6M USD -7.33%
Operating Income (Loss) -46.9M USD +16.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.6M USD +9.45%
Income Tax Expense (Benefit) 11.8M USD +99.3%
Net Income (Loss) Attributable to Parent -56.4M USD -2.22%
Earnings Per Share, Basic -1.15 USD/shares -18.6%
Earnings Per Share, Diluted -1.15 USD/shares -18.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.8M USD -4.42%
Assets, Current 161M USD +20.6%
Property, Plant and Equipment, Net 7.42M USD -18.2%
Operating Lease, Right-of-Use Asset 28.4M USD -21.9%
Other Assets, Noncurrent 12.3M USD +52.3%
Assets 354M USD -7.29%
Accounts Payable, Current 2.24M USD +47.1%
Employee-related Liabilities, Current 7.02M USD +8.94%
Contract with Customer, Liability, Current 24K USD 0%
Liabilities, Current 32.1M USD +29.5%
Contract with Customer, Liability, Noncurrent 175K USD -12.1%
Operating Lease, Liability, Noncurrent 39.1M USD -13.5%
Other Liabilities, Noncurrent 1.89M USD -68.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 7K USD
Retained Earnings (Accumulated Deficit) -966M USD -6.21%
Stockholders' Equity Attributable to Parent 176M USD -17.6%
Liabilities and Equity 354M USD -7.29%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.02M USD +90.9%
Net Cash Provided by (Used in) Financing Activities -1.72M USD +96.9%
Net Cash Provided by (Used in) Investing Activities 17M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 49.5M shares +2.87%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 38.6M USD -4.33%
Deferred Tax Assets, Valuation Allowance 436M USD +1.32%
Deferred Tax Assets, Gross 452M USD +0.96%
Operating Lease, Liability 49.8M USD +1.35%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -56.3M USD -2%
Lessee, Operating Lease, Liability, to be Paid 62.9M USD -4.84%
Property, Plant and Equipment, Gross 29.8M USD -2.71%
Operating Lease, Liability, Current 10.7M USD +173%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.4M USD +4.33%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.2M USD +188%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) -513K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 13.1M USD +29.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.7M USD +4.32%
Deferred Tax Assets, Operating Loss Carryforwards 154M USD +0.82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 230K shares 0%
Unrecognized Tax Benefits 83.7M USD +5.27%
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.7M USD +2.27%
Additional Paid in Capital 1.14B USD +1.68%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 16M USD -8.03%
Share-based Payment Arrangement, Expense 21.4M USD -15.7%
Interest Expense 2.43M USD -49.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%